▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Accessibility Log In Help

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Todd Campbell

tmfebcapital

@ebcapital

Todd has been helping buy side portfolio managers as an independent researcher for over a decade. In 2003, Todd founded E.B. Capital Markets, LLC, a research firm providing action oriented ideas to professional investors. Todd has provided insight to a variety of publications, including SmartMoney, Barron's, and CNN/fn.

Recent Articles by Todd Campbell

abbvie top

Oct 28, 2016 by Todd Campbell

AbbVie's Viekira Pak Sales Plummet in Q3

Viekira Pak's market share in the U.S. continues to slump as prescribers shift to shorter therapies that pose less of a burden on patients.

Oct 28, 2016 by Todd Campbell

Why McKesson's Stock Is Tumbling 24% Today

Disappointing quarterly results and a downbeat outlook from management are weighing on share prices.

market crash image getty 2

Oct 27, 2016 by Todd Campbell

Why Theravance Biopharma Inc Shares Tumbled 19.5% Today

Theravance Biopharma announced a stock and debt offering that disappointed investors.

abmd impella

Oct 27, 2016 by Todd Campbell

Why Abiomed Is Falling 10.2% Today

Abiomed's fiscal second quarter financials failed to impress investors looking for better.

celgene-pills-from-website_large

Oct 27, 2016 by Todd Campbell

Celgene Delivers a Blockbuster Quarter

Growth for key drugs including Revlimid and Otezla helped this big-cap biotech roll out impressive quarterly results today.

money in a pill getty

Oct 27, 2016 by Todd Campbell

Bioverativ Could Be Why Investors Should Buy Biogen

The fast-approaching spinoff of Biogen's hemophilia business may make picking up shares in Biogen a savvy move.

man on cliff GettyImages-512151814

Oct 27, 2016 by Todd Campbell

Merck & Co.'s Patent Cliff In 2017

The expiration of patents on some of the company's top-selling drugs poses big headwinds for investors.

Oct 27, 2016 by Todd Campbell

Is This the Most Important Take-Away From Exact Sciences Third Quarter Results?

Exact Sciences' operating expenses are leveling off and that may help it become profitable sooner than some think.

novartis

Oct 26, 2016 by Todd Campbell

Novartis' Is Challenging Biogen on Biogen's Own Turf

Sales of Novartis' oral MS drug Gilenya are growing more quickly than Biogen's Tecfidera in 2016.

dplo

Oct 26, 2016 by Todd Campbell

Why Diplomat Pharmacy, Inc. Shares Are Falling 13.6% Today

The departure of two senior executives is raising concerns among investors in this specialty pharmacy stock.

Oct 25, 2016 by Todd Campbell

Why Edwards Lifesciences' Q3 Results Aren't Bad News

A recent FDA approval significantly expands the company's addressable patient population in aortic stenosis.

Oct 25, 2016 by Todd Campbell

Why Corbus Pharma Cratered 18.5% Today

After a strongly bearish article on TheStreet.com blasted the company's only treatment candidate, resunab, investors in Corbus Pharma fled for the exits.

pills and dollars flickr user chris potter

Oct 25, 2016 by Todd Campbell

Merck & Co.'s Keytruda Is "Off to The Races"

Keytruda sales are already growing rapidly, but a recent approval in first-line, non-small-cell lung cancer could be about to make sales climb even more quickly.

gild hq 2

Oct 20, 2016 by Todd Campbell

Gilead Sciences: Is the Bar Set Low Enough for a Beat?

Gilead Sciences shares are struggling this year because of intense competition in hepatitis C, and soon investors will find out if the third quarter offered any signs that pricing pressure is easing.

GettyImages-507404698

Oct 24, 2016 by Todd Campbell, Neha Chamaria, Matt DiLallo, Steve Symington, and Timothy Green

Like Growth? Then You'll Love These 5 Stocks

Great growth stocks can be tough to find, but our Motley Fool contributors have found five companies across different sectors of the market that they believe are second to none.

SALE GettyImages-481429367

Oct 18, 2016 by Todd Campbell, Daniel Miller, and Timothy Green

3 Top Bargain Stocks to Buy Today

Top stocks like Polaris Industries, Skechers, and Gilead Sciences sometimes go on sale, and when they do, it can be profit-friendly to buy them.

Oct 18, 2016 by Todd Campbell

Is This Risky Biotech Stock About to Jump Higher?

A promising brain cancer drug could make Celldex Therapeutics an intriguing clinical-stage biotech to buy.

waiting GettyImages-476111824

Oct 16, 2016 by Todd Campbell, Neha Chamaria, and Daniel Miller

Why You Should Wait to Buy These 3 Stocks

Rather than rushing in and buying shares in these companies, investors may be better off sitting on the sidelines.

pills and dollars flickr user chris potter

Oct 19, 2016 by Todd Campbell

Keeping It Real: Fact-Checking Trump and Clinton on Obamacare

Donald Trump and Hillary Clinton faced off on healthcare during last Sunday's debate, and some of their claims didn't pass muster.

Oct 15, 2016 by Todd Campbell and Kristine Harjes

Fact or Fiction? Scrutinizing Trump and Clinton on Obamacare

Donald Trump and Hillary Clinton discussed Obamacare during the second presidential debate. Here's what they said, why they said it, and whether their comments during the debate were true or false.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services